https://www.yiliao.com/index.php?action=history&feed=atom&title=%E8%8D%AF%E7%89%A9%E5%86%8D%E6%8C%91%E6%88%98
药物再挑战 - 版本历史
2026-04-18T18:37:24Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E8%8D%AF%E7%89%A9%E5%86%8D%E6%8C%91%E6%88%98&diff=315653&oldid=prev
2026年1月25日 (日) 11:31 77921020
2026-01-25T11:31:34Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月25日 (日) 11:31的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l86" >第86行：</td>
<td colspan="2" class="diff-lineno">第86行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[EGFR]]</strong> 突变肺癌</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[EGFR]]</strong> 突变肺癌</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">TKI <del class="diffchange diffchange-inline">$\rightarrow$ </del>化疗 <del class="diffchange diffchange-inline">$\rightarrow$ </del><strong>TKI 再挑战</strong></td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">TKI <ins class="diffchange diffchange-inline">→ </ins>化疗 <ins class="diffchange diffchange-inline">→ </ins><strong>TKI 再挑战</strong></td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> 患者对奥希替尼耐药后接受化疗。化疗期间，耐药克隆被压制，敏感克隆复苏。再次使用奥希替尼可能获得数月的 PFS。</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> 患者对奥希替尼耐药后接受化疗。化疗期间，耐药克隆被压制，敏感克隆复苏。再次使用奥希替尼可能获得数月的 PFS。</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l93" >第93行：</td>
<td colspan="2" class="diff-lineno">第93行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[ALK]]</strong> 阳性肺癌</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[ALK]]</strong> 阳性肺癌</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">三代药 <del class="diffchange diffchange-inline">$\rightarrow$ </del><strong>一代药再挑战</strong></td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">三代药 <ins class="diffchange diffchange-inline">→ </ins><strong>一代药再挑战</strong></td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> 基于基因检测结果。若发现 <strong>[[L1198F]]</strong> 突变，回用克唑替尼是标准操作，疗效往往惊人。</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> 基于基因检测结果。若发现 <strong>[[L1198F]]</strong> 突变，回用克唑替尼是标准操作，疗效往往惊人。</div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=%E8%8D%AF%E7%89%A9%E5%86%8D%E6%8C%91%E6%88%98&diff=315652&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-25T11:29:06Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>药物再挑战</strong>（Drug Re-challenge）是指在肿瘤患者对某种药物（通常是靶向药或化疗药）产生耐药并停药一段时间（称为“药物假期”或穿插其他治疗）后，再次给予患者同一种药物进行治疗的临床策略。其生物学基础主要有两点：一是<strong>克隆动力学</strong>，即在停药期间，对药物敏感的肿瘤克隆可能重新占据主导地位（Resensitization）；二是<strong>遗传进化</strong>，即肿瘤在后续治疗压力下进化出了特殊的“<strong>[[复敏突变]]</strong>”（如 <strong>[[L1198F]]</strong>），使得先前的药物重新有效。这一策略常用于多线治疗失败、无新药可用的晚期癌症患者。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Drug Re-challenge</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Clinical Strategy (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:Tumor_clonal_evolution_drug_holiday.png|100px|停药期间敏感克隆的复苏]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">敏感株归来</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">治疗性质</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">挽救性治疗 (Salvage)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心前提</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">曾对该药<strong>有效</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">成功标志</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;">再次获得缓解 (PR/SD)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">适用癌种</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">肺癌, 结直肠癌, 卵巢癌</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键辅助</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[液体活检]]</strong> (ctDNA监测)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">风险因素</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">疾病爆发进展 (Flare)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">相关概念</th><br />
<td style="padding: 6px 12px; color: #0f172a;">药物假期 (Drug Holiday)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">为什么“回头草”能吃？</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
药物再挑战并非盲目尝试，而是基于严谨的肿瘤进化生物学原理：<br />
</p><br />
<br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">1. 适应性代价 (Fitness Cost)</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
在没有药物的环境下，耐药细胞（Resistant Clones）通常不如敏感细胞（Sensitive Clones）长得快。<br />
<br>• <strong>停药期间：</strong> 当患者停用 TKI 接受化疗时，药物选择压力消失，残留的敏感细胞因为生长优势重新扩增，逐渐取代了耐药细胞。<br />
<br>• <strong>再挑战时：</strong> 肿瘤的主要成分变回了敏感株，此时再用老药又会有效。<br />
</p><br />
</div><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>2. 悖论突变 (Paradoxical Mutation)：</strong> <br />
<br>这是最硬核的证据。如 ALK 阳性患者在三代药耐药后出现 <strong>[[L1198F]]</strong> 突变，直接在分子结构层面恢复了对一代药 <strong>[[克唑替尼]]</strong> 的结合能力。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床应用场景大盘点</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #eff6ff; border-bottom: 2px solid #60a5fa; color: #1e40af;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 20%;">癌种/靶点</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 30%;">再挑战模式</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 50%;">典型案例与证据</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[EGFR]]</strong> 突变肺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">TKI $\rightarrow$ 化疗 $\rightarrow$ <strong>TKI 再挑战</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><br />
患者对奥希替尼耐药后接受化疗。化疗期间，耐药克隆被压制，敏感克隆复苏。再次使用奥希替尼可能获得数月的 PFS。<br />
</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[ALK]]</strong> 阳性肺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">三代药 $\rightarrow$ <strong>一代药再挑战</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><br />
基于基因检测结果。若发现 <strong>[[L1198F]]</strong> 突变，回用克唑替尼是标准操作，疗效往往惊人。<br />
</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[卵巢癌]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">铂类敏感复发</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><br />
只要“无铂间期”（Platinum-Free Interval）超过 6 个月，再次使用含铂化疗是标准方案。这是“再挑战”最成熟的领域。<br />
</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">结直肠癌 (CRC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">抗 EGFR 单抗再挑战</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><br />
CRICKET 研究：RAS 野生型患者对西妥昔单抗耐药后，经过一段时间化疗，血液中 RAS 突变丰度下降，此时再用西妥昔单抗有效。<br />
</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">成功的关键：精准时机</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
并不是所有人都适合再挑战，时机和证据是关键：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>中间间隔越长越好：</strong> 停用该靶向药的时间（Drug Holiday）越长，敏感克隆恢复的空间越大，再挑战成功率越高。</li><br />
<li style="margin-bottom: 12px;"><strong>液体活检指导：</strong> 通过 <strong>ctDNA</strong> 动态监测耐药突变（如 EGFR T790M 或 KRAS 突变）的丰度变化。当耐药突变丰度降至检测线以下时，是再挑战的最佳窗口期。</li><br />
<li style="margin-bottom: 12px;"><strong>初始疗效要好：</strong> 如果患者第一次使用该药时就无效（原发耐药），那么再挑战绝对无效。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Siravegna G, et al. (2015).</strong> <em>Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.</em> <strong>[[Nature Medicine]]</strong>.<br><br />
<span style="color: #475569;">[原理基石]：通过 ctDNA 追踪发现，停药后 RAS 耐药突变克隆会呈现指数级衰减，为抗 EGFR 抗体的再挑战提供了坚实的生物学证据。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Shaw AT, et al. (2016).</strong> <em>Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.</em> <strong>[[New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[经典案例]：报道了 ALK 阳性肺癌中通过基因突变实现的“被动”再挑战，证明了回用一代药的合理性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Grommes C, et al. (2020).</strong> <em>Osimertinib Rechallenge in Patients With EGFR-Mutant Non-Small Cell Lung Cancer.</em> <strong>[[Lung Cancer]]</strong>.<br><br />
<span style="color: #475569;">[临床实践]：回顾性分析显示，奥希替尼再挑战的疾病控制率（DCR）可达 60% 以上，是后线治疗的重要选择。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
药物再挑战 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">驱动因素</td><br />
<td style="padding: 10px 15px; color: #334155;">敏感克隆复苏 • <strong>[[悖论突变]]</strong> (如 L1198F)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">必备条件</td><br />
<td style="padding: 10px 15px; color: #334155;">既往有效 • 停药间隔长 • 无其他更好选择</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">监测工具</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[ctDNA]]</strong> (液体活检) • 组织活检</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">区别概念</td><br />
<td style="padding: 10px 15px; color: #334155;">不同于“跨线治疗”(Cross-over) 或“维持治疗”</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020